Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant Mycobacterium tuberculosis 11-kDa allergen (also known as rCFP-10) is a diagnostic skin test reagent developed by Beijing Xiangrui Bioproducts for the detection of *Mycobacterium tuberculosis* infection. The product contains the recombinant 10-kDa culture filtrate protein (CFP-10), an antigen encoded by the RD1 genomic region of *M. tuberculosis*, which is absent in the *Bacillus Calmette-Guérin* (BCG) vaccine strain and most non-tuberculous mycobacteria. This absence allows the test to differentiate between true TB infection and prior BCG vaccination, addressing a major limitation of the traditional tuberculin purified protein derivative (PPD) test. Upon intradermal administration, the allergen induces a delayed-type hypersensitivity (DTH) response in individuals with T-cell memory of *M. tuberculosis*, which is then measured by the diameter of skin induration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant mycobacterium tuberculosis 11-kDa allergen.